COMPASS Pathways plc to Post FY2027 Earnings of $0.19 Per Share, HC Wainwright Forecasts (NASDAQ:CMPS)

COMPASS Pathways plc (NASDAQ:CMPS - Free Report) - HC Wainwright increased their FY2027 earnings per share estimates for shares of COMPASS Pathways in a research report issued on Friday, August 23rd. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of $0.19 for the year, up from their previous estimate of $0.15. HC Wainwright currently has a "Buy" rating and a $120.00 target price on the stock. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.24) per share. HC Wainwright also issued estimates for COMPASS Pathways' FY2028 earnings at $4.55 EPS.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.03). During the same period in the prior year, the company earned ($0.62) EPS.

Several other research analysts have also recently weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a report on Friday, June 21st. Royal Bank of Canada began coverage on shares of COMPASS Pathways in a report on Tuesday, July 23rd. They issued an "outperform" rating and a $23.00 price target on the stock. Finally, Canaccord Genuity Group cut their price target on shares of COMPASS Pathways from $50.00 to $48.00 and set a "buy" rating for the company in a research report on Friday, August 2nd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $47.40.

COMPASS Pathways Stock Performance

CMPS stock traded up $0.81 during midday trading on Monday, reaching $8.00. 2,988,971 shares of the company's stock traded hands, compared to its average volume of 555,077. The company has a 50-day moving average price of $6.84 and a two-hundred day moving average price of $8.25. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.23 and a current ratio of 15.23. COMPASS Pathways has a 52 week low of $5.01 and a 52 week high of $12.75. The firm has a market capitalization of $547.05 million, a PE ratio of -3.38 and a beta of 2.27.

Institutional Trading of COMPASS Pathways

Several institutional investors have recently added to or reduced their stakes in CMPS. Quest Partners LLC bought a new stake in shares of COMPASS Pathways in the fourth quarter worth about $33,000. Blue Trust Inc. bought a new stake in shares of COMPASS Pathways in the second quarter worth about $81,000. Conservest Capital Advisors Inc. bought a new stake in shares of COMPASS Pathways in the fourth quarter worth about $91,000. EWA LLC bought a new stake in shares of COMPASS Pathways in the fourth quarter worth about $107,000. Finally, Kennedy Capital Management LLC bought a new stake in shares of COMPASS Pathways in the first quarter worth about $139,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.